<http://schema.org/description>
"Novartis'multiple sclerosis (MS) drug Gilenya continues to show its efficacy in treating patients in the long run. Novartis presented new data on Gilenya from three pivotal studies - TRANSFORMS, FREEDOMS and FREEDOMS extension studies."^^<http://www.w3.org/2001/XMLSchema#string>
<https://www.zacks.com/stock/news/111194/encouraging-data-on-novartis-gilenya>